Targets › VZV
6 programs from 5 companies in 12 trials: 4 Phase 2, 4 Phase 1, 2 Phase 4, 2 Phase 3; Infectious disease, Vaccines, Immunology; next expected readout Dec 2026.
Open in Phaseline: the race on VZV, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Peking University Third Hospital | Brivudine Nucleoside analog antiviral inhibiting herpes zoster virus DNA polymerase | VZV | Phase 4 | Herpes Zoster | Dec 2026 |
| University of Sao Paulo General Hospital | Acyclovir Human herpesvirus 1 DNA polymerase inhibitor | HSV1, HSV2, VZV | Phase 4 | Autoimmune Rheumatic Diseases | Apr 2027 |
| MAXVAX Biotechnology Limited Liability Company | Varicella Zoster Virus Envelope Glycoprotein E Envelope glycoprotein E vaccine antigen | VZGP5, VZV | Phase 3 | Herpes Zoster | Nov 2027 |
| Guangzhou Patronus Biotech | LYB004 Recombinant varicella zoster virus glycoprotein E (VZV-gE) vaccine adjuvanted with A01B or | VZV | Phase 2 | Herpes Zoster (HZ); Herpes Zoster | Dec 2026 |
| Green Cross | MG1111 (BARICELA) Varicella-zoster virus vaccine | VZV | Phase 2 | Varicella | Jun 2027 |
| MAXVAX Biotechnology Limited Liability Company | Recombinant Herpes Zoster Vaccine (CHO cells) with low dose MA105 Recombinant varicella zoster virus glycoprotein E vaccine with low dose MA105 adjuvant | VZV, VZVA | Phase 2 | Herpes Zoster | – |
Herpes Zoster (8) Herpes Zoster (HZ) (2) Varicella (1) Autoimmune Rheumatic Diseases (1)
protein or peptide (2), small molecule (2), other (1), mixed (1)
MAXVAX Biotechnology Limited Liability Company (2) Green Cross (1) Guangzhou Patronus Biotech (1) University of Sao Paulo General Hospital (1) Peking University Third Hospital (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.